Literature DB >> 19782679

Inhibition of recombinant Ca(v)3.1 (alpha(1G)) T-type calcium channels by the antipsychotic drug clozapine.

Kee-Hyun Choi1, Hyewhon Rhim.   

Abstract

Low voltage-activated T-type calcium channels are involved in the regulation of the neuronal excitability, and could be subject to many antipsychotic drugs. The effects of clozapine, an atypical antipsychotic drug, on recombinant Ca(v)3.1 T-type calcium channels heterologously expressed in human embryonic kidney 293 cells were examined using whole-cell patch-clamp recordings. At a standard holding potential of -100 mV, clozapine inhibited Ca(v)3.1 currents with an IC(50) value of 23.7+/-1.3 microM in a use-dependent manner. However, 10 microM clozapine inhibited more than 50% of the Ca(v)3.1 currents in recordings at a more physiologically relevant holding potential of -75 mV. Clozapine caused a significant hyperpolarizing shift in the steady-state inactivation curve of the Ca(v)3.1 channels, which is presumably the main mechanism accounting for the inhibition of the Ca(v)3.1 currents. In addition, clozapine slowed Ca(v)3.1 deactivation and inactivation kinetics but not activation kinetics. Clozapine-induced changes in deactivation and inactivation rates of the Ca(v)3.1 channel gating would likely facilitate calcium influx via Ca(v)3.1 T-type calcium channels. Thus, clozapine may exert its therapeutic and/or side effects by altering cell's excitability and firing properties through actions on T-type calcium channels.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19782679     DOI: 10.1016/j.ejphar.2009.09.035

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  13 in total

1.  De novo mutations in schizophrenia disrupt genes co-expressed in fetal prefrontal cortex.

Authors:  Suleyman Gulsuner; Jon M McClellan
Journal:  Neuropsychopharmacology       Date:  2014-01       Impact factor: 7.853

2.  Dysregulated corticostriatal activity in open-field behavior and the head-twitch response induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine.

Authors:  Claudia Rangel-Barajas; Ana María Estrada-Sánchez; Scott J Barton; Robert R Luedtke; George V Rebec
Journal:  Neuropharmacology       Date:  2016-11-02       Impact factor: 5.250

3.  Effects of the T-type calcium channel antagonist Z944 on paired associates learning and locomotor activity in rats treated with the NMDA receptor antagonist MK-801.

Authors:  Andrew J Roebuck; Wendie N Marks; Max C Liu; Nimra B Tahir; Nadine K Zabder; Terrance P Snutch; John G Howland
Journal:  Psychopharmacology (Berl)       Date:  2018-09-24       Impact factor: 4.530

4.  Disrupted leptin-fatty acid biosynthesis is an early manifestation of metabolic abnormalities in schizophrenia.

Authors:  Mohammad M Khan
Journal:  World J Psychiatry       Date:  2022-06-19

5.  Spatial and temporal mapping of de novo mutations in schizophrenia to a fetal prefrontal cortical network.

Authors:  Suleyman Gulsuner; Tom Walsh; Amanda C Watts; Ming K Lee; Anne M Thornton; Silvia Casadei; Caitlin Rippey; Hashem Shahin; Vishwajit L Nimgaonkar; Rodney C P Go; Robert M Savage; Neal R Swerdlow; Raquel E Gur; David L Braff; Mary-Claire King; Jon M McClellan
Journal:  Cell       Date:  2013-08-01       Impact factor: 41.582

Review 6.  Microglial intracellular Ca(2+) signaling as a target of antipsychotic actions for the treatment of schizophrenia.

Authors:  Yoshito Mizoguchi; Takahiro A Kato; Hideki Horikawa; Akira Monji
Journal:  Front Cell Neurosci       Date:  2014-11-05       Impact factor: 5.505

Review 7.  Drug elucidation: invertebrate genetics sheds new light on the molecular targets of CNS drugs.

Authors:  Donard S Dwyer; Eric Aamodt; Bruce Cohen; Edgar A Buttner
Journal:  Front Pharmacol       Date:  2014-07-28       Impact factor: 5.810

8.  Long-term Use of Clozapine is Protective for Bone Density in Patients with Schizophrenia.

Authors:  Chieh-Hsin Lin; Chun-Yuan Lin; Hong-Song Wang; Hsien-Yuan Lane
Journal:  Sci Rep       Date:  2019-03-07       Impact factor: 4.379

Review 9.  Pathogenesis and management of Brugada syndrome in schizophrenia: A scoping review.

Authors:  Anuj Rastogi; Dylan Viani-Walsh; Shareef Akbari; Nicholas Gall; Fiona Gaughran; John Lally
Journal:  Gen Hosp Psychiatry       Date:  2020-10-06       Impact factor: 3.238

10.  Targeting Neural Synchrony Deficits is Sufficient to Improve Cognition in a Schizophrenia-Related Neurodevelopmental Model.

Authors:  Heekyung Lee; Dino Dvorak; André A Fenton
Journal:  Front Psychiatry       Date:  2014-02-14       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.